Alx Oncology Holdings (ALXO) Enterprise Value (2019 - 2026)
Alx Oncology Holdings (ALXO) reported Enterprise Value of -$140.3 million for Q1 2026, down 43.44% on a YoY basis from -$248.1 million in Q1 2025, and down 213.29% sequentially from -$44.8 million in Q4 2025.
Alx Oncology Holdings (ALXO) Enterprise Value (2019 - 2026) Analysis & Trends
Alx Oncology Holdings (ALXO) has 8 years of Enterprise Value data on file, last reported at -$140.3 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 43.44% year-over-year to -$140.3 million; the trailing twelve-month figure through Mar 2026 stood at -$140.3 million (down 43.44% YoY), and the FY2025 full-year result was -$44.8 million, up 64.94% from the prior year.
- Enterprise Value retreated to -$140.3 million in Q1 2026, from -$44.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$44.8 million in Q4 2025 to a low of -$316.6 million in Q1 2022.
- A 5-year average of -$176.9 million and a median of -$157.4 million in 2024 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value soared 64.94% in 2025 and plunged 43.44% in 2026, its largest moves.
- Tracing ALXO's Enterprise Value over 5 years: stood at -$266.2 million in 2022, then jumped by 31.36% to -$182.7 million in 2023, then soared by 30.09% to -$127.8 million in 2024, then soared by 64.94% to -$44.8 million in 2025, then plunged by 213.29% to -$140.3 million in 2026.
- Business Quant data shows ALXO's Enterprise Value at -$140.3 million in Q1 2026, -$44.8 million in Q4 2025, and -$60.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Alx Oncology Holdings | 211.24 Mn | 211.24 Mn | - | -140.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -140.32 Mn |
| Dec 31, 2025 | -44.79 Mn |
| Sep 30, 2025 | -60.63 Mn |
| Jun 30, 2025 | -79.31 Mn |
| Mar 31, 2025 | -97.83 Mn |
| Dec 31, 2024 | -127.76 Mn |
| Sep 30, 2024 | -148.57 Mn |
| Jun 30, 2024 | -156.72 Mn |
| Mar 31, 2024 | -157.44 Mn |
| Dec 31, 2023 | -182.74 Mn |
| Sep 30, 2023 | -190.01 Mn |
| Jun 30, 2023 | -212.84 Mn |
| Mar 31, 2023 | -227.94 Mn |
| Dec 31, 2022 | -266.21 Mn |
| Sep 30, 2022 | -284.91 Mn |
| Jun 30, 2022 | -313.37 Mn |
| Mar 31, 2022 | -316.60 Mn |
| Dec 31, 2021 | -363.67 Mn |
| Sep 30, 2021 | -385.15 Mn |
| Jun 30, 2021 | -409.96 Mn |